RareResearch.AI
← Back to atlas

F397C

Category 3/4 — Most DruggableUncertain significanceTransmembrane · predictedSource card
PhenylalanineCysteine at position 397 · Cytoplasmic loop 2 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type F397 — hydrogen bond to A393
Fullscreen ↗
DynaMut2 mutant · F397C
Mutant C397 — polar contact to H401 lost (9 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

9 lost0 gained11 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondA393A393Preserved
Hydrogen bondE394E394Preserved
Hydrogen bondH401H401Preserved
Polar contactA393A393Preserved
Polar contactE394E394Preserved
Polar contactV395V395Preserved
Polar contactW399Lost
Polar contactN400N400Preserved
Polar contactH401H401Preserved
Aromatic / πW371Lost
Aromatic / πF374Lost
Aromatic / πH401Lost
Van der WaalsG257Lost
Van der WaalsW371Lost
Van der WaalsV395V395Preserved
Van der WaalsH401Lost
HydrophobicA370Lost
HydrophobicW371W371Preserved
HydrophobicF374F374Preserved
HydrophobicH401Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-1.21kcal/mol
Destabilising — moderate
AlphaMissense
0.994
likely pathogenic
AlphaFold pLDDT
82
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsAutosomal dominant nonsyndromic hearing loss 6; Type 2 diabetes mellitus; Wolfram syndrome 1; Cataract 41; Wolfram-like syndrome
Population frequency (gnomAD v4)Ultra-rare · AF 0.00012%
cDNA changec.1190T>G
ClinVar accessionVCV001960347
Last evaluated2026/01/17 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — F397C Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Phenylalanine → Cysteine at position 397. Cytoplasmic loop 2. ClinVar Uncertain significance, AlphaMissense 0.994, DynaMut2 ΔΔG -1.21 kcal/mol (destabilising).


Identity

FieldValue
VariantF397C (p.Phenylalanine397Cysteine)
DNA changec.1190T>G
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV001960347
Amino acid changePhenylalanine (F) → Cysteine (C)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 39781.94 — well-folded
DomainCytoplasmic loop 2
Position contextLoop region · position 397 sits between transmembrane segments, solvent-accessible
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 397 sits in a connecting loop between transmembrane helices. Loop residues are typically solvent-exposed and often contribute to interhelical contacts or serve as recognition sites for binding partners. The wild-type residue is large aromatic hydrophobic (phenylalanine); the mutant is thiol (cysteine — disulfide-capable, free -SH). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.9936
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-1.21 (Destabilising)
Job ID178092136578
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092136578

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Last evaluated2026/01/17 00:00
InheritanceAutosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscapeF397C is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Autosomal dominant nonsyndromic hearing loss 6
  • Type 2 diabetes mellitus
  • Wolfram syndrome 1
  • Cataract 41
  • Wolfram-like syndrome

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=1.21 < 2 kcal/mol (fold intact) + AlphaMissense 0.994 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=1.21 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.994. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • F397C_molstar_viewer.html — interactive 3D viewer (auto-highlights position 397 with ball-and-stick + neighbors within 5Å)
  • F397C_variant_card.md — this card (source of truth)
  • F397C_variant_card.html — styled printable card
  • F397C_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • F397C_wildtype_interactions.pse / F397C_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the F397C PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download F397C PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.